Wells Fargo has initiated coverage on NewAmsterdam Pharma Company NV (NAMS) with an Overweight rating, marking the firm’s first assessment of the biotechnology company. This decision underscores Wells Fargo's positive outlook based on its research into NewAmsterdam’s business model and growth prospects.
NewAmsterdam Pharma, headquartered in Naarden, Netherlands, specializes in developing oral therapies for patients at high risk of cardiovascular disease. The company is currently focused on obicetrapib, a low-dose, once-daily cholesteryl ester transfer protein (CETP) inhibitor aimed at lowering low-density lipoprotein cholesterol (LDL-C) as an adjunct to statin therapy. Its innovative approach positions it well within the clinical-stage biopharmaceutical landscape, particularly as it also explores obicetrapib in combination therapies for conditions such as Alzheimer’s disease.
As of November 20, 2025, NewAmsterdam Pharma boasts a market capitalization of $4.3 billion, with a trailing twelve-month earnings per share (EPS) of -2.02. The company is set to report its next earnings on August 4, 2026, with an EPS estimate of -0.47.
Analyst ratings like this one provide insights based on rigorous financial analysis, yet they also reflect assumptions that may not always align with actual market developments. Investors are encouraged to consider multiple factors, including company fundamentals and industry trends, when making decisions. Analyst opinions can evolve over time, and differing views may exist among financial professionals regarding the same company.